Updated survival and secondary safety and efficacy analyses from CA 209-678: a phase 2, open-label, single-center study of Y90-radioembolization in combination with nivolumab in asian patients with advanced hepatocellular carcinoma (Gastroenterol Hepatol (N Y), 2021)
(11, Suppl 6):